2022
Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection
Lodi S, Klein M, Rauch A, Epstein R, Wittkop L, Logan R, Rentsch C, Justice A, Touloumi G, Berenguer J, Jarrin I, Egger M, Puoti M, Monforte A, Gill J, Ceron D, van Sighem A, Linas B, van der Valk M, Hernán M, Collaboration H. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection. Journal Of The International AIDS Society 2022, 25: e26048. PMID: 36562643, PMCID: PMC9784654, DOI: 10.1002/jia2.26048.Peer-Reviewed Original ResearchConceptsSustained virological responseHCV RNA testingDAA treatmentSVR ratesVirological responseProbability of SVRHepatitis C virus (HCV) cureRoutine HCV RNA testingActing antiviral (DAA) treatmentDAA treatment initiationCD4 cell countDirect antiviral agentsPresence of cirrhosisHCV RNA testEnd of treatmentClinical strataDAA recipientsHIV-HCVSVR assessmentSVR statusHIV acquisitionClinical characteristicsAntiviral treatmentTreatment initiationHCV genotypesDevelopment and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV
Kim HN, Nance RM, Re V, Silverberg MJ, Franco R, Sterling TR, Cachay ER, Horberg MA, Althoff KN, Justice AC, Moore RD, Klein M, Crane HM, Delaney JA, Kitahata MM. Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 89: 396-404. PMID: 35202048, PMCID: PMC8887786, DOI: 10.1097/qai.0000000000002886.Peer-Reviewed Original ResearchMeSH KeywordsBayes TheoremEnd Stage Liver DiseaseHepatitis B, ChronicHepatitis CHIV InfectionsHumansMaleMiddle AgedConceptsEnd-stage liver diseaseLiver diseaseNorth American AIDS Cohort CollaborationStandardized medical record reviewAccessible clinical parametersHIV-specific factorsChronic hepatitis BFibrosis-4 indexMedical record reviewSpontaneous bacterial peritonitisHarrell's C-statisticHepatitis B virusHepatitis C virusAlcohol use disorderRisk prediction modelRace/ethnicityCohort CollaborationESLD riskHepatic impairmentVariceal bleedHepatitis BBacterial peritonitisHepatic encephalopathyRecord reviewClinical parameters
2020
Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals
Do A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG, Tate JP, Re VL, Justice AC. Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. Journal Of General Internal Medicine 2020, 35: 2025-2034. PMID: 32342483, PMCID: PMC7352003, DOI: 10.1007/s11606-020-05782-6.Peer-Reviewed Original ResearchConceptsDAA treatmentExcess weight gainTreatment initiationWeight gainChronic hepatitis C virus (HCV) infectionHigh FIB-4 scoreHepatitis C virus infectionC virus infectionFIB-4 scoreHepatitis C infectionDirect acting antiviralsLiver disease progressionMultiple logistic regressionConclusionWeight gainDAA therapySVR achievementC infectionBaseline weightProspective studyExcess weightDisease progressionVirus infectionHigh riskPatientsBirth cohortFIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C
So-Armah KA, Lim JK, Re V, Tate JP, Chang CH, Butt AA, Gibert CL, Rimland D, Marconi VC, Goetz MB, Ramachandran V, Brittain E, Long M, Nguyen KL, Rodriguez-Barradas MC, Budoff MJ, Tindle HA, Samet JH, Justice AC, Freiberg MS, Team V. FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. Progress In Cardiovascular Diseases 2020, 63: 184-191. PMID: 32068085, PMCID: PMC7278895, DOI: 10.1016/j.pcad.2020.02.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsFemaleHealth StatusHeart FailureHepatitis CHIV InfectionsHIV Long-Term SurvivorsHumansIncidenceLiver CirrhosisMaleMiddle AgedPrognosisRisk AssessmentRisk FactorsSeverity of Illness IndexStroke VolumeTime FactorsUnited StatesVentricular Function, LeftVeterans HealthViral LoadConceptsType of HFIncident heart failureHeart failureHepatitis C statusAdvanced fibrosisLiver fibrosisEjection fractionHazard ratioC statusVeterans Aging Cohort StudyRisk of HFpEFLast clinic visitReduced ejection fractionAging Cohort StudyLiver fibrosis scoresPrevalent cardiovascular diseaseFirst HF eventProportional hazards modelIncident HFpEFHepatitis CClinic visitsCohort studyPrimary outcomeFibrosis scoreHF events
2019
Integrated stepped alcohol treatment for patients with HIV and liver disease: A randomized trial
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Deng Y, Fiellin LE, O'Connor PG, Bedimo R, Gibert CL, Marconi VC, Rimland D, Rodriguez-Barradas MC, Simberkoff MS, Tate JP, Justice AC, Bryant KJ, Fiellin DA. Integrated stepped alcohol treatment for patients with HIV and liver disease: A randomized trial. Journal Of Substance Use And Addiction Treatment 2019, 106: 97-106. PMID: 31540617, PMCID: PMC7244228, DOI: 10.1016/j.jsat.2019.08.007.Peer-Reviewed Original ResearchPatterns and Correlates of Prescription Opioid Receipt Among US Veterans: A National, 18-Year Observational Cohort Study
Rentsch CT, Edelman EJ, Justice AC, Marshall BDL, Xu K, Smith AH, Crystal S, Gaither JR, Gordon AJ, Smith RV, Kember RL, Polimanti R, Gelernter J, Fiellin DA, Tate JP, Kranzler HR, Becker WC. Patterns and Correlates of Prescription Opioid Receipt Among US Veterans: A National, 18-Year Observational Cohort Study. AIDS And Behavior 2019, 23: 3340-3349. PMID: 31317364, PMCID: PMC7344341, DOI: 10.1007/s10461-019-02608-3.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid receiptCohort studyLong-term opioid therapyVeterans Aging Cohort StudyLatent growth mixture modellingPrescription opioid receiptObservational cohort studyAging Cohort StudyOpioid therapyCause mortalityHepatitis COpioid prescriptionsFuture prevention researchOUD diagnosisGrowth mixture modellingUS veteransHigh prevalenceLow doseHigh incidenceUse disordersPrevention researchGenetic discoveriesReceiptHIVRegional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus
Njei B, Esserman D, Krishnan S, Ohl M, Tate JP, Hauser RG, Taddei T, Lim J, Justice AC. Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus. Medical Care 2019, 57: 279-285. PMID: 30807449, PMCID: PMC6436819, DOI: 10.1097/mlr.0000000000001071.Peer-Reviewed Original ResearchConceptsDirect-acting antiviral agentsHepatitis C virus infectionVeterans Affairs Healthcare SystemRural-Urban Commuting Area codesCurative HCV treatmentRural-urban designationC virus infectionElectronic health record dataHepatitis C virusPrior treatment experienceLower odds ratioHealth record dataZone improvement plan codeEligible patientsHCV treatmentAntiretroviral medicationsRural-urban residenceLiver diseaseUnadjusted analysesC virusRural-urban differencesOdds ratioMultivariable modelLower incidenceObservational studyMedical Intensive Care Unit Admission Among Patients With and Without HIV, Hepatitis C Virus, and Alcohol-Related Diagnoses in the United States
Rentsch CT, Tate JP, Steel T, Butt AA, Gibert CL, Huang L, Pisani M, Soo Hoo GW, Crystal S, Rodriguez-Barradas MC, Brown ST, Freiberg MS, Graber CJ, Kim JW, Rimland D, Justice AC, Fiellin DA, Crothers KA, Akgün KM. Medical Intensive Care Unit Admission Among Patients With and Without HIV, Hepatitis C Virus, and Alcohol-Related Diagnoses in the United States. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 80: 145-151. PMID: 30422912, PMCID: PMC6701630, DOI: 10.1097/qai.0000000000001904.Peer-Reviewed Original ResearchConceptsHepatitis C virusAlcohol-related diagnosesAdmission ratesMICU admissionAdmission riskC virusRelative riskIntensive care unit admission rateMedical intensive care unit admissionAge-adjusted admission ratesHCV mono-infected patientsIntensive care unit admissionVeterans Aging Cohort StudyHCV care providersCare unit admissionAging Cohort StudyAdjusted rate ratiosConfidence intervalsVeterans Health AdministrationUnhealthy alcohol useHIV monoHIV-/HCVUnit admissionCause hospitalizationHCV infection
2017
DNA methylation signatures of illicit drug injection and hepatitis C are associated with HIV frailty
Zhang X, Hu Y, Justice AC, Li B, Wang Z, Zhao H, Krystal JH, Xu K. DNA methylation signatures of illicit drug injection and hepatitis C are associated with HIV frailty. Nature Communications 2017, 8: 2243. PMID: 29269866, PMCID: PMC5740109, DOI: 10.1038/s41467-017-02326-1.Peer-Reviewed Original ResearchConceptsIllicit drug injectionHepatitis C infectionWhite blood cellsIllicit drug useCo-occurring conditionsMethylation signaturesDiscovery sampleC infectionHepatitis CEpigenome-wide association analysisLower frailtyDrug injectionHigh frailtyImmune functionHealth outcomesDrug useFrailtyDNA methylation signaturesBlood cellsHIVReplication sampleEpigenetic programmingSignificant CpGsEpigenetic effectsIndividuals
2016
Reply to: “Hepatitis C testing in U.S. veterans born 1945–1965: An update”
Justice AC, Esserman D, Sarkar S, Levin FL, Skanderson M, Lim JK. Reply to: “Hepatitis C testing in U.S. veterans born 1945–1965: An update”. Journal Of Hepatology 2016, 66: 239. PMID: 27717863, DOI: 10.1016/j.jhep.2016.09.019.Peer-Reviewed Original ResearchRisk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras
Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Re V, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie EE, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice A, Peters MG, Goedert JJ, Mayor A, Thio CL, Cachay ER, Moore R, Research and Design of IeDEA F, Kirk G, Benson C, Bosch R, Boswell S, Mayer K, Grasso C, Hogg R, Harrigan P, Montaner J, Cescon A, Samji H, Brooks J, Buchacz K, Gebo K, Moore R, Moore R, Rodriguez B, Horberg M, Silverberg M, Thorne J, Goedert J, Jacobsonc L, D'Souza G, Klein M, Rourke S, Burchell A, Rachlis A, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Patel P, Brooks J, Saag M, Mugavero M, Willig J, Eron J, Napravnik S, Kitahata M, Crane H, Kim H, Drozd D, Sterling T, Haas D, Bebawy S, Turner M, Justice A, Dubrow R, Fiellin D, Gange S, Anastos K, Moore R, Saag M, Gange S, Kitahata M, Althoff K, McKaig R, Justice A, Freeman A, Moore R, Freeman A, Lent C, Kitahata M, Van Rompaey S, Crane H, Drozd D, Morton L, McReynolds J, Lober W, Gange S, Althoff K, Abraham A, Lau B, Zhang J, Jing J, Golub E, Modur S, Wong C, Hogan B, Tong W, Liu B. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clinical Infectious Diseases 2016, 63: 1160-1167. PMID: 27506682, PMCID: PMC5064164, DOI: 10.1093/cid/ciw531.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseUse of antiretroviralsESLD riskAntiretroviral therapyLiver diseaseNorth American AIDS Cohort CollaborationTime-updated CD4 cell countModern antiretroviral therapy (ART) eraAntiretroviral therapy eraTenofovir-based regimensCD4 cell countModern antiretroviral therapyHuman immunodeficiency virusIncidence rate ratiosRate ratioCohort CollaborationCoinfected PersonsTherapy eraHCV therapyHIV RNAHepatitis BHepatitis statusImmunodeficiency virusC virusAntiretroviral eraHepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection
Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Re V, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA. Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal Of Substance Use And Addiction Treatment 2016, 68: 62-67. PMID: 27431048, PMCID: PMC4976086, DOI: 10.1016/j.jsat.2016.06.002.Peer-Reviewed Original ResearchConceptsLiver enzyme elevationAlcohol use disorderUninfected patientsHepatotoxic medicationsHCV infectionUse disordersComposite endpointLiver injuryHIV/HCV co-infected patientsHCV co-infected patientsHIV/HCV statusPre-existing liver injuryCo-infected patientsCohort of HIVHepatitis C infectionHIV/HCVOpioid use disorderRisk of hepatotoxicityHCV statusHepatic safetyMedian ALTC infectionChart reviewEnzyme elevationHIV infectionIsolated Hepatitis B Core Antibody is Associated With Advanced Hepatic Fibrosis in HIV/HCV Infection But Not in HIV Infection Alone
Bhattacharya D, Tseng CH, Tate JP, Re V, Gibert CL, Butt AA, Brown ST, Lim JK, Rodriguez-Barradas MC, Rimland D, Kaufman E, Justice AC, Goetz MB. Isolated Hepatitis B Core Antibody is Associated With Advanced Hepatic Fibrosis in HIV/HCV Infection But Not in HIV Infection Alone. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2016, 72: e14-e17. PMID: 26829660, PMCID: PMC4837046, DOI: 10.1097/qai.0000000000000941.Peer-Reviewed Original ResearchDisparities in hepatitis C testing in U.S. veterans born 1945–1965
Sarkar S, Esserman DA, Skanderson M, Levin FL, Justice AC, Lim JK. Disparities in hepatitis C testing in U.S. veterans born 1945–1965. Journal Of Hepatology 2016, 65: 259-265. PMID: 27130843, PMCID: PMC4955712, DOI: 10.1016/j.jhep.2016.04.012.Peer-Reviewed Original ResearchMeSH KeywordsHepacivirusHepatitis CHepatitis C AntibodiesHumansMaleRisk FactorsUnited StatesVeteransConceptsUnited States Preventative Services Task ForceHCV testingHCV antibodiesRisk factorsHepatitis C virus testingHepatitis C virus infectionHealth systemVeterans Administration Health SystemBirth cohort testingHCV testing practicesHepatitis C testingNational screening policyPositive HCV RNAPredictors of testingC virus infectionVA health systemAdvanced liver fibrosisVeterans Administration dataCorporate Data WarehouseHCV positivityHCV RNAAdvanced fibrosisHCV testLiver fibrosisVirus infection
2015
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals
May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte A, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 348-354. PMID: 25848927, PMCID: PMC4506784, DOI: 10.1097/qai.0000000000000603.Peer-Reviewed Original ResearchConceptsInjection drug useDrug useLiver-related mortalityHepatitis C infectionEffect of HCVMortality hazard ratioNorth American cohortHCV coinfectionHCV statusAntiretroviral therapyC infectionHepatitis CHazard ratioSurvival differencesRisk factorsExcess mortalityPoor survivalRisk groupsHCVAmerican cohortHIVNew treatmentsMortalitySubstantial proportionComplete data
2014
End-Stage Renal Disease Among HIV-Infected Adults in North America
Abraham A, Althoff K, Jing Y, Estrella M, Kitahata M, Wester C, Bosch R, Crane H, Eron J, Gill M, Horberg M, Justice A, Klein M, Mayor A, Moore R, Palella F, Parikh C, Silverberg M, Golub E, Jacobson L, Napravnik S, Lucas G, AIDS F, Kirk G, Benson C, Bosch R, Collier A, Boswell S, Grasso C, Mayer K, Hogg R, Harrigan R, Montaner J, Cescon A, Brooks J, Buchacz K, Gebo K, Moore R, Moore R, Carey J, Rodriguez B, Horberg M, Silverberg M, Thorne J, Goedert J, Jacobson L, Klein M, Rourke S, Burchell A, Rachlis A, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Saag M, Mugavero M, Willig J, Eron J, Napravnik S, Kitahata M, Crane H, Justice A, Dubrow R, Fiellin D, Sterling T, Haas D, Bebawy S, Turner M, Gange S, Anastos K, Moore R, Saag M, Gange S, Althoff K, Kitahata M, McKaig R, Justice A, Freeman A, Moore R, Freeman A, Lent C, Kitahata M, Van Rompaey S, Crane H, Webster E, Morton L, Simon B, Gange S, Althoff K, Abraham A, Lau B, Zhang J, Jing J, Golub E, Modur S, Hanna D, Rebeiro P, Wong C, Mendes A. End-Stage Renal Disease Among HIV-Infected Adults in North America. Clinical Infectious Diseases 2014, 60: 941-949. PMID: 25409471, PMCID: PMC4357817, DOI: 10.1093/cid/ciu919.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseSex-standardized incidence ratiosRisk of ESRDDiabetes mellitusESRD casesBlack racePredictors of ESRDNorth American AIDS Cohort CollaborationHepatitis C virus coinfectionC virus coinfectionESRD risk factorsIncident ESRD casesHuman immunodeficiency virusHigh viral loadMajority of casesCohort CollaborationVirologic suppressionESRD incidencePrior AIDSRenal transplantViral suppressionInject drugsRenal diseaseVirus coinfectionBlack patientsHIV infection, antiretroviral therapy initiation and longitudinal changes in biomarkers of organ function.
So-Armah KA, Chang J, Alcorn C, Lo Re V, Baker JV, Tracy R, Butt AA, Agan BK, Rimland D, Gibert CL, Goetz MB, Oursler KK, Rodriguez-Barradas MC, Kuller LH, Brown ST, Stein JH, Skanderson M, Justice AC, Freiberg MS. HIV infection, antiretroviral therapy initiation and longitudinal changes in biomarkers of organ function. Current HIV Research 2014, 12: 50-9. PMID: 25034208, PMCID: PMC4495647, DOI: 10.2174/1570162x1201140716101512.Peer-Reviewed Original ResearchConceptsART initiationHIV infectionHIV infection levelsViral suppressionLongitudinal changesLDL cholesterolPositive HIV antibody testBiomarker measurementsAge-related chronic diseasesAntiretroviral therapy initiationEnd-organ diseaseFIB-4 scoreHIV antibody testWilcoxon signedrank testUninfected veteransVACS-VCFIB-4Therapy initiationHIV levelsHDL cholesterolSerum levelsTotal cholesterolPlatelet countMean ageChronic diseases
2013
Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus–Coinfected Veterans
Anderson JP, Tchetgen E, Re V, Tate JP, Williams PL, Seage GR, Horsburgh CR, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Klein MB, Justice AC. Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus–Coinfected Veterans. Clinical Infectious Diseases 2013, 58: 719-727. PMID: 24285848, PMCID: PMC3922212, DOI: 10.1093/cid/cit779.Peer-Reviewed Original ResearchConceptsHepatitis C virusInitiation of ARTAntiretroviral therapyHepatic decompensationHazard ratioVeterans Aging Cohort Study Virtual CohortHIV/HCV-coinfected patientsHuman immunodeficiency virus (HIV) coinfectionEnd-stage liver diseaseHepatic decompensation eventsIncident hepatic decompensationLiver disease outcomesCombination antiretroviral therapyImmunodeficiency virus coinfectionHospital discharge diagnosisSpontaneous bacterial peritonitisCopies/mLMarginal structural modelsART initiationART regimenDecompensation eventsHIV RNAVariceal hemorrhageBacterial peritonitisLiver failureAcetaminophen receipt among HIV‐infected patients with advanced hepatic fibrosis
Edelman EJ, Gordon KS, Re V, Skanderson M, Fiellin DA, Justice AC, Team F. Acetaminophen receipt among HIV‐infected patients with advanced hepatic fibrosis. Pharmacoepidemiology And Drug Safety 2013, 22: 1352-1356. PMID: 24285468, PMCID: PMC4164158, DOI: 10.1002/pds.3517.Peer-Reviewed Original ResearchConceptsAdvanced hepatic fibrosisAcetaminophen exposureHCV statusHepatic fibrosisHIV/HCV-coinfected patientsVeterans Aging Cohort StudyAdvanced liver fibrosisAging Cohort StudyAcetaminophen-induced hepatotoxicitySample of HIVCross-sectional associationsPolytomous logistic regressionAlcohol use disorderCross-sectional analysisAcetaminophen prescriptionsAcetaminophen useHIV-monoinfectedFIB-4Cohort studyLiver injuryPlatelet countLiver fibrosisAlanine aminotransferaseHIVPatientsHepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals
Lucas G, Jing Y, Sulkowski M, Abraham A, Estrella M, Atta M, Fine D, Klein M, Silverberg M, Gill M, Moore R, Gebo K, Sterling T, Butt A, for the NA-ACCORD of the IeDEA, Kirk G, Benson C, Bosch R, Collier A, Boswell S, Grasso C, Mayer K, Hogg R, Harrigan R, Montaner J, Cescon A, Brooks J, Buchacz K, Gebo K, Moore R, Carey J, Rodriguez B, Horberg M, Silverberg M, Horberg M, Thorne J, Goedert J, Jacobson L, Klein M, Rourke S, Burchell A, Rachlis A, Rico P, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Patel P, Brooks J, Saag M, Mugavero M, Willig J, Eron J, Napravnik S, Kitahata M, Crane H, Justice A, Dubrow R, Fiellin D, Sterling T, Haas D, Bebawy S, Turner M, Gange S, Anastos K, Moore R, Saag M, Gange S, Kitahata M, McKaig R, Justice A, Freeman A, Moore R, Freeman A, Lent C, Kitahata M, Van Rompaey S, Crane H, Webster E, Morton L, Simon B, Gange S, Althoff K, Abraham A, Lau B, Zhang J, Jing J, Golub E, Modur S, Hanna D, Rebeiro P, Wong C, Mendes A. Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. The Journal Of Infectious Diseases 2013, 208: 1240-1249. PMID: 23904290, PMCID: PMC3778973, DOI: 10.1093/infdis/jit373.Peer-Reviewed Original ResearchConceptsStage 3 CKDStage 5 CKDProgressive CKDAviremic subjectsHazard ratioGlomerular filtration rate decreaseChronic kidney disease riskHepatitis C virus replicationHCV seronegative subjectsHCV viremic subjectsAdjusted hazard ratioChronic kidney diseaseHepatitis C viremiaKidney disease riskConfidence intervalsC virus replicationAdvanced CKDAviremic individualsCKD incidenceHCV-viremicSeronegative subjectsC viremiaViremic subjectsKidney diseaseCKD